Latest revenue
—
as of 2025-12-31
Latest net income
$-106.2M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think AURA is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for AURA.
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage biotechnology company developing precision therapies to treat solid tumors designed to preserve organ function. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with early choroidal melanoma (defined as small choroidal melanoma and/or indeterminate lesions) and is also in clinical development for other ocular oncology indications and bladder cancer. There is significant unmet need for novel treatments for patients with choroidal melanoma, given the limitations of the current standard of care, or SoC, and patient reluctance to undergo radiotherapy in the form of either plaque brachytherapy or…
AI summary unavailable — showing raw filing excerpt
Generated from AURA's filing dated 2026-03-30
Key risks
Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. You should carefully read and consider all of the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes thereto and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. Unless otherwise indicated, references to our business being harmed in these risk factors will include harm to our business,…
AI summary unavailable — showing raw filing excerpt
Generated from AURA's filing dated 2026-03-30
Profitability
Return on equity
-77.6%
35.6%Return on assets
-62.7%
31.6%Leverage
Debt / equity
0.24×
18.2%Debt / assets
19.2%
14.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-33.7M | -22.6% | — |
Q4 2025 2025-12-31 | — | — | $-25.6M | +1.1% | — |
Q3 2025 2025-09-30 | — | — | $-26.1M | -24.2% | — |
Q2 2025 2025-06-30 | — | — | $-27.0M | -32.9% | — |
Q1 2025 2025-03-31 | — | — | $-27.5M | -39.5% | — |
Q4 2024 2024-12-31 | — | — | $-25.8M | — | — |
Q3 2024 2024-09-30 | — | — | $-21.0M | -13.7% | — |
Q2 2024 2024-06-30 | — | — | $-20.3M | -11.1% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on AURA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$40.0M
Net activity
−$40.0M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AURA
Institutional value
$99.0M
Total shares held
14.8M
Distinct holders
62
-55 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3.6M | $24.0M | +26.2K (+0.7%) | Added |
| 2 | Medicxi Ventures Management (Jersey) Ltd | 3.0M | $20.3M | +0 (+0.0%) | No change |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $15.0M | — | New |
| 4 | FRANKLIN RESOURCES INC | 2.1M | $13.9M | -125.7K (-5.7%) | Trimmed |
| 5 | LEVIN CAPITAL STRATEGIES, L.P. | 941.4K | $6.3M | -94.2K (-9.1%) | Trimmed |
| 6 | DIMENSIONAL FUND ADVISORS LP | 558.2K | $3.7M | +40.2K (+7.8%) | Added |
| 7 | Regency Capital Management Inc.\DE | 532.5K | $3.6M | -6.1K (-1.1%) | Trimmed |
| 8 | VANGUARD FIDUCIARY TRUST CO | 397.2K | $2.7M | — | New |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 391.3K | $2.6M | — | New |
| 10 | UBS Group AG | 118.9K | $795.5K | -52.7K (-30.7%) | Trimmed |
| 11 | Bank of New York Mellon Corp | 99.4K | $665.2K | -8.5K (-7.9%) | Trimmed |
| 12 | BNP PARIBAS FINANCIAL MARKETS | 90.1K | $602.5K | -24.6K (-21.4%) | Trimmed |
| 13 | Fisher Asset Management, LLC | 83.5K | $558.7K | — | New |
| 14 | Nuveen, LLC | 72.7K | $486.4K | +378 (+0.5%) | Added |
| 15 | RHUMBLINE ADVISERS | 64.7K | $433.0K | -314 (-0.5%) | Trimmed |
| 16 | TBH Global Asset Management, LLC | 60.3K | $403.6K | +0 (+0.0%) | No change |
| 17 | TD ASSET MANAGEMENT INC | 40.5K | $271.0K | +0 (+0.0%) | No change |
| 18 | Vanguard Global Advisers, LLC | 39.8K | $266.2K | — | New |
| 19 | DEUTSCHE BANK AG\ | 38.0K | $254.0K | +7.1K (+23.2%) | Added |
| 20 | Invesco Ltd. | 34.3K | $229.3K | +7.0K (+25.6%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AURA's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.